Suppr超能文献

南非约翰内斯堡耐药结核病确诊患者的治疗启动情况。

Treatment initiation among persons diagnosed with drug resistant tuberculosis in Johannesburg, South Africa.

作者信息

Evans Denise, Schnippel Kathryn, Govathson Caroline, Sineke Tembeka, Black Andrew, Long Lawrence, Berhanu Rebecca, Rosen Sydney

机构信息

Health Economics and Epidemiology Research Office, Department of Internal Medicine, School of Clinical Medicine, Faculty of Health Sciences, University of the Witwatersrand, Johannesburg, South Africa.

Right to Care, Johannesburg, South Africa.

出版信息

PLoS One. 2017 Jul 26;12(7):e0181238. doi: 10.1371/journal.pone.0181238. eCollection 2017.

Abstract

BACKGROUND

In South Africa, roughly half of the drug-resistant TB cases diagnosed are reported to have been started on treatment. We determined the proportion of persons diagnosed with rifampicin resistant (RR-) TB who initiated treatment in Johannesburg after the introduction of decentralized RR-TB care in 2011.

METHODS

We retrospectively matched adult patients diagnosed with laboratory-confirmed RR-TB in Johannesburg from 07/2011-06/2012 with records of patients initiating RR-TB treatment at one of the city's four public sector treatment sites (one centralized, three decentralized). Patients were followed from date of diagnosis until the earliest of RR-TB treatment initiation, death, or 6 months' follow-up. We report diagnostic methods and outcomes, proportions initiating treatment, and median time from diagnosis to treatment initiation.

RESULTS

594 patients were enrolled (median age 34 (IQR 29-42), 287 (48.3%) female). Diagnosis was by GenoType MTBDRplus (Hain-Life-Science) line probe assay (LPA) (281, 47.3%), Xpert MTB/RIF (Cepheid) (258, 43.4%), or phenotypic drug susceptibility testing (DST) (30, 5.1%) with 25 (4.2%) missing a diagnosis method. 320 patients (53.8%) had multi-drug resistant TB, 158 (26.6%) rifampicin resistant TB by Xpert MTB/RIF, 102 (17.2%) rifampicin mono-resistance, and 14 (2.4%) extensively drug-resistant TB. 256/594 (43.0%) patients initiated treatment, representing 70.7% of those who were referred for treatment (362/594). 338/594 patients (57.0%) did not initiate treatment, including 104 (17.5%) who died before treatment was started. The median time from sputum collection to treatment initiation was 33 days (IQR 12-52).

CONCLUSION

Despite decentralized RR-TB treatment, fewer than half the patients diagnosed in Johannesburg initiated appropriate treatment. Offering treatment at decentralized sites alone is not sufficient; improvements in linking patients diagnosed with RR-TB to effective treatment is essential.

摘要

背景

在南非,据报告约有一半确诊的耐多药结核病病例开始接受治疗。我们确定了2011年引入分散式耐利福平结核病(RR-TB)治疗后,在约翰内斯堡确诊为耐利福平(RR-)结核病并开始治疗的患者比例。

方法

我们回顾性地将2011年7月至2012年6月在约翰内斯堡确诊为实验室确诊RR-TB的成年患者与在该市四个公共部门治疗点之一(一个集中式,三个分散式)开始RR-TB治疗的患者记录进行匹配。从诊断日期开始对患者进行随访,直至最早开始RR-TB治疗、死亡或随访6个月。我们报告诊断方法和结果、开始治疗的比例以及从诊断到开始治疗的中位时间。

结果

共纳入594例患者(中位年龄34岁(四分位间距29-42岁),287例(48.3%)为女性)。诊断采用GenoType MTBDRplus(Hain-Life-Science)线性探针分析(LPA)(281例,47.3%)、Xpert MTB/RIF(Cepheid)(258例,43.4%)或表型药敏试验(DST)(30例,5.1%),25例(4.2%)未记录诊断方法。320例患者(53.8%)患有耐多药结核病,158例(26.6%)通过Xpert MTB/RIF检测为耐利福平结核病,102例(17.2%)为耐利福平单耐药,14例(2.4%)为广泛耐药结核病。256/594(43.0%)例患者开始治疗,占被转诊接受治疗患者的70.7%(362/594)。338/594例患者(57.0%)未开始治疗,其中104例(17.5%)在开始治疗前死亡。从痰液采集到开始治疗的中位时间为33天(四分位间距12-52天)。

结论

尽管采用了分散式RR-TB治疗,但在约翰内斯堡确诊的患者中,只有不到一半开始了适当的治疗。仅在分散式地点提供治疗是不够的;改善将确诊为RR-TB的患者与有效治疗联系起来的工作至关重要。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4346/5529007/ffb359e54091/pone.0181238.g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验